Learn More
Medical treatment and chemotherapy are seldom successful in achieving objective tumour reduction in patients with metastatic neuroendocrine tumours. Treatment with the radiolabelled somatostatin analogue [(90)Y-DOTA(0),Tyr(3)]octreotide may result in partial remissions in 10-25% of patients. The newer analogue [DOTA(0),Tyr(3)]octreotate (octreotate) has a(More)
We studied the diagnostic accuracy of single-photon emission computed tomography (SPECT) with technetium 99m-labeled hexamethylpropylene amine oxime (Tc 99m HMPAO) in 48 patients with probable Alzheimer's disease (AD) according to NINCDS-ADRDA criteria and in 60 controls recruited from a population-based study. With logistic regression, we identified(More)
Somatostatin analogs are used in the control of hormonal hypersecretion and tumor growth of patients with acromegaly, islet cell carcinomas and carcinoids. Recently we showed that somatostatin receptor positive tumors can be visualized in vivo after the administration of radioactive isotope-labelled somatostatin analogs. Receptor imaging was positive in(More)
PURPOSE Adequate dosimetry is mandatory for effective and safe peptide receptor radionuclide therapy (PRRT). Besides the kidneys, the bone marrow is a potentially dose-limiting organ. The radiation dose to the bone marrow is usually calculated according to the MIRD scheme, where the accumulated activity in the bone marrow is calculated from the accumulated(More)
The shape, size and location of regions of interest (ROIs) show considerable variability between single-photon emission tomography (SPET) studies in aging and Alzheimer's disease, but the possible influence on study results remains unknown. We compared three different ROIs in a SPET study with 60 controls and in 48 patients with probable Alzheimer's disease(More)
come correlated with histopathological data. The terminology of the new WHO classification (NET G1/G2; neuroendocrine carcinoma (NEC) G3) [4] is utilized in this article in concert with the former appellation (well-differentiated endocrine tumor/carcinoma; poorly differentiated endocrine carcinoma). Of note, this does not imply that grading has been(More)
The endocrine tumours of the gastrointestinal tract have been attracting the attention of clinicians since their very fi rst identifi cation, which paralleled the identifi ca-tion of gut endocrine cells. The history of enteroendocrine cells and derived tumours begins with the early development of histology and histochemistry, dating back to the end of the(More)
age peak in the 6th and 7th decades of life [1]. The frequency of multicentricity lies between 26 and 30% [3, 4] and 15–29% of tumors are associated with other non-car-cinoid malignancies [5–7]. The WHO classification subdivides jejunal-ileal tumors, similar to other gastroen-teropancreatic endocrine tumors, into three general categories [8] : (1)(More)
General The incidence of clinically detected PETs has been reported to be 4–12 per million, which is much lower than that reported from autopsy series (about 1%) [2, 3]. Considering functioning PETs, insulinomas are the most common (17% incidence), followed by gastrinoma (15%). The remainder incorporates RFTs and includes: VIPoma (2%), glucagonoma (1%),(More)
Although it was originally believed that thyroid hormones enter target cells by passive diffusion, it is now clear that cellular uptake is effected by carrier-mediated processes. Two stereospecific binding sites for each T4 and T3 have been detected in cell membranes and on intact cells from humans and other species. The apparent Michaelis-Menten values of(More)